Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers
Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers
复制标题
DOI：
10.1007/s10147-021-02045-0
复制
发表时间：
2021-10-11
影响因子：
3.3
通讯作者：
Shimada, Hideaki
中科院分区：
文献类型：
--
作者：
Nanami, Tatsuki;Hoshino, Isamu;Shimada, Hideaki
研究背景RalA是Ras超家族的一员。抗RalA自身抗体（s-RalA-Abs）在各种类型的癌症中充当肿瘤标志物，并且与p53自身抗体（s-p53-Abs）负相关。本研究旨在评估s-RalA-Abs和s-p53-Abs在不同类型癌症中的关系。方法1833例癌症患者（食管癌172例，肝癌91例，肺癌269例，胃癌317例，结肠癌262例，乳腺癌364例，前列腺癌358例）和73例健康体检者纳入研究。采用酶联免疫吸附试验分析s-RalA-Abs和s-p53-Abs的水平，评价两种自身抗体的阳性率及其相关性。s-RalA abs和s-p53 abs的截止值设定为平均值± 2标准差，高于截止值的值定义为阳性。结果各型胃癌患者血清中抗体滴度均明显高于对照组（P < 0.01）。s-RalA-Abs的阳性率在11.7%和21.5%之间，s-p53-Abs的阳性率在12%和28.5%之间。两种抗体的联合检测显示阳性率分别为20.9%和44.2%。在0/I/II期肿瘤中，两种抗体组合的阳性率范围为21.5%至42.3%。这两种自身抗体在前列腺癌和乳腺癌中是互补的，但在其他癌症中是独立的。结论联合应用s-RalA-Abs和s-p53-Abs可提高包括0/I/II期在内的所有肿瘤的阳性率。
Background RalA is a member of the Ras superfamily of small GTPases. The Anti-RalA autoantibodies (s-RalA-Abs) act as tumor markers in various types of cancer and are negatively associated with the p53 autoantibodies (s-p53-Abs). This study aimed to evaluate the relationship between s-RalA-Abs and s-p53-Abs in various types of cancer. Methods A total of 1833 cancer patients (esophageal cancer, 172; hepatocellular carcinoma, 91; lung cancer, 269; gastric cancer, 317; colon cancer, 262; breast cancer, 364; and prostate cancer, 358) and 73 healthy subjects were enrolled in the study. The levels of s-RalA-Abs and s-p53-Abs were analyzed using enzyme-linked immunosorbent assay, and the positivity rates and relations between the two autoantibodies were evaluated. The cutoff values for s-RalA abs and s-p53 abs were set as mean + 2 standard deviation and the values higher than the cutoff values were defined as positive. Results The titers in all cancer types were significantly higher than those in the controls (P < 0.01). The positivity rates for s-RalA-Abs ranged between 11.7 and 21.5%, and those for s-p53-Abs ranged between 12 and 28.5%. A combined assay of the two antibodies revealed positivity rates of 20.9 and 44.2%. In Stage 0/I/II tumors, the positivity rates of the combination of the two antibodies ranged between 21.5 and 42.3%. The two autoantibodies were complementary to each other in the prostate and breast cancers, but independent in other carcinomas. Conclusion The combined use of s-RalA-Abs and s-p53-Abs tended to increase the positivity rate in all cancers, including Stage 0/I/II cancers.